|
  
- 现金
- 6395 元
- 精华
- 0
- 帖子
- 3365
- 注册时间
- 2007-6-13
- 最后登录
- 2023-2-10
|
Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
Sep 25, 2018 at 7:30 AM EDT
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 25, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events: The 14th Annual Meeting of the Oligonucleotide Therapeutics Society – Seattle , September 30-October 3, 2018 October 1
PDF Version
PASADENA, Calif.--(BUSINESS WIRE)--Sep. 25, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the following upcoming events:
The 14th Annual Meeting of the Oligonucleotide Therapeutics Society– Seattle, September 30-October 3, 2018
October 1, 9:20 a.m. PDT – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver an oral presentation titled, “Direct conjugation approaches in RNAi come of age – Successful delivery outside of hepatocytes”
October 1, 5:00 p.m. PDT – Rui Zhu, Ph.D., Arrowhead’s senior process chemist, will deliver an oral presentation titled, “Subcutaneous delivery of an effective RNA interference (RNAi) therapeutic candidate silencing angiopoietin-like protein 3 for treatment of hyperlipidemia”
October 3,4:00 p.m. PDT – James Hamilton M.D., MBA,Arrowhead’s vice president of clinical development, will deliver an invited, late-breaker oral presentation titled, “Clinical Development of RNAi Therapeutics for HBV and Alpha-1 Antitrypsin Deficiency”
2018 Cantor Fitzgerald Global Healthcare Conference– New York, October 1-3, 2018
October 2, 10:55 a.m. EDT –Christopher Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will deliver a corporate presentation
2018 International HBV Meeting - The Molecular Biology of Hepatitis B – Taormina, Italy, October 3-6, 2018
October 5, 1:00 p.m. CEST –Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver a poster presentation titled, “Gene expression analysis during and after RNAi treatment of chronically HBV infected chimpanzees”
Chardan 2nd Annual Genetic Medicines Conference– New York, October 9, 2018
October 9, 1:00 p.m. EDT –Bruce Given, M.D., Arrowhead’s chief operating officer, will participate in a fireside chat
Arrowhead Analyst and Investor R&D Day – New York, October 16, 2018
October 16, 1:00 p.m. EDT – Arrowhead management and external key opinion leaders will discuss Arrowhead’s emerging pipeline of RNAi therapeutics
North American Cystic Fibrosis Conference– Denver, October 18-20, 2018
October 18, 11:15 a.m. MDT –Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “A novel targeted RNAi molecule (TRiM™) delivery platform for the therapeutic inhibition of ENaC in cystic fibrosis lung disease”
A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website. |
|
发表于 2018-9-26 19:02
